https://www.selleckchem.com/pr....oducts/compound-3i.h
Through extensive illustrations, we strongly encourage wider reporting of false discovery rates for observed findings. Tenofovir alafenamide (TAF) has a less favorable effect on lipids compared to TDF (Tenofovir disoproxil fumarate) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CH are scarce. This study is to evaluate the effects of TAF on the lipids of 237 CHB patients, compared with TDF, inactive CHB, and non-HBV infected control groups, using propensity score-matching (PSM). Fo
Respect!
Kommentar
Delen
